← 返回

单细胞功能基因组学揭示血液癌症中对 NK 细胞敏感性和耐药性的决定因素

英文原题:Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers.

查看英文原题

Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers.

PubMed 2023/12/12(内容时间) Immunity Q1 · IF 30.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌细胞对自然杀伤(NK)细胞介导的细胞毒性具有不同的敏感性,但其背后的决定因素尚不完全清楚。为系统解析这一问题,我们对多种癌细胞系进行了全基因组CRISPR筛选,并结合单细胞转录组读出,以研究NK细胞与癌细胞的相互作用。NK细胞与癌细胞的相互作用诱导了不同的激活状态和I型干扰素(IFN)反应,其模式取决于癌细胞谱系,从较敏感的髓系肿瘤到较不敏感的B淋巴细胞肿瘤不等。在癌细胞中进行的CRISPR筛选揭示了调控NK细胞介导杀伤敏感性和抵抗性的基因,包括黏附相关糖蛋白、蛋白聚糖、IFN基因以及转录调控因子,同时证实了抗原呈递和死亡受体信号通路的重要性。结合单细胞转录组读出的CRISPR筛选为潜在机制提供了深入见解,包括癌细胞中IFN-γ信号的调控以及NK细胞激活状态。我们的发现凸显了影响不同癌症中NK细胞敏感性的机制多样性,并为基于NK细胞的疗法提供了资源。

展开英文摘要原文

Cancer cells can evade natural killer (NK) cell activity, thereby limiting anti-tumor immunity. To reveal genetic determinants of susceptibility to NK cell activity, we examined interacting NK cells and blood cancer cells using single-cell and genome-scale functional genomics screens. Interaction of NK and cancer cells induced distinct activation and type I interferon (IFN) states in both cell types depending on the cancer cell lineage and molecular phenotype, ranging from more sensitive myeloid to less sensitive B-lymphoid cancers.

CRISPR screens in cancer cells uncovered genes regulating sensitivity and resistance to NK cell-mediated killing, including adhesion-related glycoproteins, protein fucosylation genes, and transcriptional regulators, in addition to confirming the importance of antigen presentation and death receptor signaling pathways. CRISPR screens with a single-cell transcriptomic readout provided insight into underlying mechanisms, including regulation of IFN-γ signaling in cancer cells and NK cell activation states.

Our findings highlight the diversity of mechanisms influencing NK cell susceptibility across different cancers and provide a resource for NK cell-based therapies.

论文信息

作者
Dufva O、Gandolfi S、Huuhtanen J、Dashevsky O、Duàn H、Saeed K、Klievink J、Nygren P
第一作者单位
Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290 Helsinki, Finland; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014 Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, 00290 Helsinki, Finland.Finland
通讯作者单位
Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, 00290 Helsinki, Finland; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014 Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, 00290 Helsinki, Finland. Electronic address: satu.mustjoki@helsinki.fi.Finland
文献类型
非美国政府资助研究 · 美国 NIH 资助研究
期刊
Immunity2023 Dec 12
原文标识
PubMed 38091953 · DOI 10.1016/j.immuni.2023.11.008